<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Phenylbutazone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00812</strong>&#160; (APRD00409, DB08343)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From <span class="caps">AMA</span> Drug Evaluations Annual, 1994, p1822)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00812/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00812/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00812.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00812.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00812.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00812.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00812.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00812">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Phenbutazone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Azolid</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Alka Phenyl Tab</td><td>Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone</td></tr><tr><td>Alka Phenylbutazone Tab</td><td>Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone</td></tr><tr><td>Phenylone Plus Tab</td><td>Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li></ul></td></tr><tr><th>CAS number</th><td>50-33-9</td></tr><tr><th>Weight</th><td>Average: 308.3743<br>Monoisotopic: 308.152477894</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>VYMDGNCVAMGZFE-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-butyl-1,2-diphenylpyrazolidine-3,5-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00812.gif?1265922771">show</a>(9.03 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Alternative parents</th><td>Pyrazolidinones; Carboxylic Acid Hydrazides; Polyamines; Carboxylic Acid Amides; Hydrazines and Derivatives</td></tr><tr><th>Substituents</th><td>pyrazolidine; carboxylic acid hydrazide; carboxamide group; carboxylic acid derivative; polyamine; hydrazine derivative; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzene and substituted derivatives. These are aromatic compounds containing at least one benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of backache and ankylosing spondylitis</td></tr><tr><th>Pharmacodynamics</th><td>Phenylbutazone is a synthetic, pyrazolone derivative. It is a nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties and arise from its ability to reduce production of prostaglandin H and prostacyclin. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostacylcin causes vascular constriction platelet disaggregation</td></tr><tr><th>Mechanism of action</th><td>Phenylbutazone binds to and inactivates prostaglandin H synthase and prostacyclin synthase through peroxide (H2O2) mediated deactivation. The reduced production of prostaglandin leads to reduced inflammation of the surrounding tissues.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, LD<sub>50</sub> = 238 mg/kg (mouse); Oral, LD<sub>50</sub> = 781 mg/kg (rabbit); Oral, LD<sub>50</sub> = 245 mg/kg (rat); Oral, LD<sub>50</sub> = 375 mg/kg (rat)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9931</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6185</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7632</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5423</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5596</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.866</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6378</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5439</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.5752</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5968</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5233</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7995
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9881
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7753 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9469
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.892
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li>
<li>Novartis pharmaceuticals corp</li>
<li>Ivax pharmaceuticals inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Sandoz inc</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>C.O. Truxton Inc.</li>
<li><a href="http://www.jaapharm.com">Jaapharm Canada Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The NSAID, phenylbutazone, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00414">Acetohexamide</a></td><td>Phenylbutazone may increase the effect of acetohexamide.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The NSAID, phenylbutazone, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The NSAID, phenylbutazone, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The NSAID, phenylbutazone, may increase the hydantoin effect of ethotoin.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The NSAID, phenylbutazone, may increase the hydantoin effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB01067">Glipizide</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB01289">Glisoxepide</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB01382">Glycodiazine</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The NSAID, phenylbutazone, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The NSAID, phenylbutazone, may increase the hydantoin effect of mephenytoin.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The NSAID, phenylbutazone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The NSAID, phenylbutazone, may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB00839">Tolazamide</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The NSAID, phenylbutazone, may increase the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce irritation. Avoid alcohol.</li></ul></td></tr></tbody></table>